Clinical Research Malaysia (CRM) – Dr. Mohamed Ali Abu Bakar, CEO
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Address: Level 6, Quill 9,
112, Jalan Semangat,
46300 Petaling Jaya,
Selangor, Malaysia.
Tel: +603 7495 2600
Web: http://gsk.com.my/
GlaxoSmithKline (GSK) is one of the world’s leaders in pharmaceutical research and development with a combination of skills and resources that provide a platform for delivering strong growth in today’s rapidly changing healthcare environment. GSK’s mission is to improve the quality of human life by enabling people to do more, feel better and live longer. With a firm foundation in science, GSK discover, develop, manufacture and distribute vaccines, prescription medicines and consumer healthcare products. Headquartered in the UK, with major business operations in the US, GSK employs more than 100,000 people in 117 countries.
In Malaysia, GSK has established a strong presence for almost 50 years. It employs close to 600 employees and has an annual sales turnover of over USD100Million.
GSK’s pharmaceutical products cover a broad spectrum of vaccines and major therapeutic areas such as anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic and oncology.
GSK is a leader in the important area of vaccines and are developing new treatments for cancer. GSK pharmaceuticals business serves more than 130 countries. The vaccines are used for immunizing children, and prevent flu and hepatitis. Every day, more than 3 million doses of GSK’s vaccines are distributed around the world.
GSK has a large portfolio of products, ranging from tablets and toothpaste to inhalers and complex capsules, in over 28,000 different pack sizes and presentations. More than 34,000 people work in GSK’s Global Manufacturing & Supply (GMS) to make and distribute these products easily and effectively to millions of people around the world. They work in 80 manufacturing sites in 37 countries.
In Malaysia, GSK wide product range covers healthcare from vaccines and over-the counter(OTC) medicines to nutritional health drink, oral care and pharmaceuticals.
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
